AbCellera Biologics (NASDAQ:ABCL) Releases Earnings Results

AbCellera Biologics (NASDAQ:ABCL) issued its quarterly earnings data on Wednesday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.04), FiscalAI reports. The company had revenue of $4.05 million during the quarter, compared to analyst estimates of $7.85 million. AbCellera Biologics had a negative net margin of 181.75% and a negative return on equity of 14.86%.

Here are the key takeaways from AbCellera Biologics’ conference call:

• ABCL635 enrollment and dosing were completed ahead of schedule, with top-line Phase I data in post-menopausal women expected shortly. Management views a clean safety profile and efficacy comparable to approved small-molecule treatments as key success criteria.
• AbCellera announced T-cell engager collaborations with Vertex and Jazz that provide more than $110 million in upfront payments, with potential downstream payments exceeding $2 billion under the Jazz agreement and tiered royalties on sales.
• ABCL688 and ABCL386 remain in IND-enabling work and are expected to enter Phase I/II studies in 2027, while the ABCL575 Phase I trial is on track for a Q4 readout; the company currently does not plan to develop ABCL575 beyond Phase I.
• Second-quarter revenue fell to approximately $4 million from $17 million a year earlier, while the net loss widened to about $55 million, or $0.18 per share, as research and development spending increased to support internal programs.
• AbCellera ended the quarter with approximately $567 million in cash and marketable securities, plus roughly $110 million in committed government funding, which management believes is sufficient to fund at least three years of pipeline investment.

AbCellera Biologics Price Performance

ABCL opened at $5.92 on Thursday. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -12.33 and a beta of 1.20. The business has a fifty day moving average price of $6.19 and a 200 day moving average price of $4.66. AbCellera Biologics has a 12 month low of $2.74 and a 12 month high of $8.44.

Institutional Investors Weigh In On AbCellera Biologics

Institutional investors have recently modified their holdings of the company. Voleon Capital Management LP purchased a new stake in AbCellera Biologics during the third quarter worth approximately $56,000. Engineers Gate Manager LP purchased a new stake in AbCellera Biologics in the fourth quarter valued at $38,000. Magnetar Financial LLC acquired a new position in AbCellera Biologics in the fourth quarter valued at $49,000. Oxford Asset Management LLP acquired a new stake in shares of AbCellera Biologics in the 4th quarter valued at about $51,000. Finally, Lantern Wealth Advisors LLC purchased a new position in AbCellera Biologics during the 2nd quarter worth approximately $51,000. 61.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on ABCL shares. JonesTrading initiated coverage on AbCellera Biologics in a research report on Friday, April 10th. They set a “buy” rating and a $11.00 price target for the company. Cantor Fitzgerald lifted their price objective on AbCellera Biologics from $11.00 to $12.00 and gave the stock an “overweight” rating in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of AbCellera Biologics in a report on Friday, July 17th. Benchmark raised shares of AbCellera Biologics from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Tuesday, July 7th. Finally, Wall Street Zen lowered AbCellera Biologics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.00.

Key Headlines Impacting AbCellera Biologics

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target on AbCellera from $11 to $12 and maintained an “overweight” rating. The new target implies substantial potential upside from the stock’s $5.92 reference price, signaling confidence in the company’s longer-term outlook. Benzinga analyst price-target update
• Positive Sentiment: AbCellera expects to report topline Phase II data for ABCL635 soon. The company also announced new T-cell engager collaborations that are expected to provide more than $110 million in upfront cash, improving near-term financial flexibility and potentially validating its antibody-discovery platform. AbCellera collaboration and ABCL635 update
• Neutral Sentiment: Investors are awaiting additional details from AbCellera’s Q2 earnings call regarding its collaboration pipeline, cash position and upcoming clinical milestones. Q2 2026 earnings call transcript
• Negative Sentiment: Q2 financial results missed expectations. AbCellera reported a loss of $0.18 per share versus the consensus estimate of a $0.14 loss, while revenue of $4.05 million fell well short of the $7.85 million forecast. The larger loss and sharply lower revenue highlight continued operating pressure and may limit gains until clinical and partnership catalysts deliver results. AbCellera Q2 2026 business results

About AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.